KEGG   NETWORK: N10009Help
Entry
N10009                      Network                                

Name
Tyrosine kinase inhibitor to HER2 overexpression/amplification
Definition
(Trastuzumab,Trastuzumab_emtansine,Pertuzumab,Lapatinib,Neratinib) -| (ERBB2*,ERBB2*)
  Expanded
(D03257,D09980,D05446,D04024,D10898) -| (2064v1,2064v3)
Class
nt06210 ERK signaling
nt06265 Bladder cancer
nt06266 Non-small cell lung cancer
nt06270 Breast cancer
nt06214 PI3K signaling
nt06262 Pancreatic cancer
nt06219 JAK-STAT signaling
nt06261 Gastric cancer
Type
Drug target
Gene
2064  ERBB2; erb-b2 receptor tyrosine kinase 2
Variant
2064v1  ERBB2 overexpression
2064v3  ERBB2 amplification
Perturbant
D03257  Trastuzumab
D09980  Trastuzumab emtansine
D05446  Pertuzumab
D04024  Lapatinib ditosylate
D10898  Neratinib maleate
Reference
  Authors
Nahta R, Hung MC, Esteva FJ
  Title
The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.
  Journal
Cancer Res 64:2343-6 (2004)
DOI:10.1158/0008-5472.CAN-03-3856
Reference
  Authors
LoRusso PM, Weiss D, Guardino E, Girish S, Sliwkowski MX
  Title
Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer.
  Journal
Clin Cancer Res 17:6437-47 (2011)
DOI:10.1158/1078-0432.CCR-11-0762
LinkDB All DBs

DBGET integrated database retrieval system